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 Notes & Additional 
Reading 
Summary and Key Points  
1. Staging of cancer occurs prior to the beginning of treatment, 
or at the first definitive surgery. Clinical staging, which 
includes radiography and exam findings, takes place initially.  
Pathologic staging, which is obtained from surgical 
specimens, can be acquired during the course of surgical 
treatment. Patients then carry either the clinical stage or the 
pathologic stage for the duration of their illness. 
 
2. Because the initial clinical or pathologic stage is carried for 
the duration of a patient’s illness, patients with Stage I 
disease who later develop metastases still have Stage I 
disease – any given cancer is only staged once.  
 
3. Specific criteria are revised periodically, but the principles of 
TNM classification are constant for all solid tumors: 
- T describes the size or extent of local invasion of the 
primary tumor 
- N describes regional lymph node involvement 
- M describes metastatic disease 
- G describes the pathologic grade of the primary tumor 
The TNM classification translates to Stage groupings, 
generally 0-4. 
 
4. Some cancers, including sarcomas, include G (grade) in the 
Stage Grouping. 
 
5. Cancer stages are created to provide prognostic information 
and guide treatment decisions. 
 
6. Leukemia, lymphoma, some pediatric malignancies, and a 
few rare adult malignancies use different staging systems that 
do not rely on TNM information.   
 
7. Restaging, a term in common use for reassessing a patient’s 
current disease state, is a misnomer. 
 
8. The American College of Surgeons requires pretreatment 
staging on the chart of each patient. All patients can be 
staged clinically. Pathologic staging provides more accurate 
information and is the one most physicians use if available. 
 
9. Staging systems are periodically revised and it is important to 
know which version was used. 
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1 Examples: Wilm’s tumor, CNS tumors, and esthesioneuroblastoma 
Overview  
The “stage” of a cancer is a short-hand way of describing the extent 
of cancer in a patient. Stage is based on macroscopic involvement of 
tissues by cancer. By contrast, the “grade” of a cancer is a 
pathologist's interpretation of how well (low grade) or poorly (high 
grade) differentiated a tumor is. Cancer grade, therefore, is a 
microscopic description of malignancy. This chapter will describe 
principles of cancer staging. 
 
  
When considering treatments for cancer, one of the first 
considerations is the stage of disease. Early stage disease has the 
best prognosis and can be most effectively treated; in some cases 
curing the disease entirely is a realistic goal. Late stage disease may 
be considered inoperable or incurable, with treatment focusing on 
palliation of symptoms and prolonging life. Treatment paradigms are 
developed for each stage of disease, and clinical trials use disease 
staging to segregate outcomes. The stage of disease must therefore 
be determined prior to any therapeutic intervention.   
 
  
For solid tumors, the tumor node metastasis (TNM) system is used.  
Although the specific categories differ by tumor type and are 
periodically revised, the TNM system itself is a common language for 
most cancers. For hematologic cancers, most pediatric and some 
rare adult tumor types,1 staging systems customized to the tumor 
type are used. 
 
  
Staging  
Clinical stage includes physical exam findings and imaging results.  
Imaging is generally performed to determine the extent of primary 
disease and to search for possible metastasis. Imaging techniques 
include X Ray, CT, MRI, and PET. Scans may encompass the area 
YouTube: Understanding 
Lung Cancer, Part III: 
Staging (3:18) 
Staging of Cancer 
Mary Linton Peters 
Richard S. Pieters, MD 
James Liebmann, MD 
Geoffrey Graeber, MD 
 
 
3 
Staging of Cancer 
07 May 2013 
NOTICE:  This material may be protected by copyright. 
                                                 
2 cStage III, T4N1M0, yStage II: T1 N1 M0 
of the primary lesion, typical sites for metastasis (spine, bone, brain, 
liver), and symptomatic areas. Any new or changed lesions found by 
imaging are considered suspicious for metastatic disease. Careful 
evaluation of regional lymph node basins may reveal enlarged 
nodes. 
  
Pathologic stage includes the results of primary tumor resection, 
lymph node biopsies, and biopsies of any suspected metastasis at 
presentation. If the definitive surgery follows neoadjuvant treatment, 
the results are reported as “y stage”, but the clinical stage is carried 
as the patient’s actual stage.2 
 
  
Biopsies  
As part of the staging process, fine needle aspirate (FNA) or core 
biopsies may be performed of the primary tumor, enlarged regional 
lymph node, or site of possible metastasis. Biopsies generally have a 
high specificity but poor sensitivity. This implies that a biopsy positive 
for malignant cells is diagnostic and adequate for pathologic staging 
of nodes or metastases. However, the absence of malignant cells in 
a biopsy sample is not sufficient to rule out cancer in patients with a 
high index of suspicion, and the suspicion is sufficient to include the 
site in clinical staging. 
 
  
The presence of malignant cells informs the TNM staging process in 
several ways: 
- pT: Biopsy is insufficient to define pathologic T Stage;           
pathologic staging requires  resection of the primary 
- pN: Confirms presence of malignant cells in regional lymph            
nodes 
- pM: Confirms presence of distant metastatic disease 
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If biopsy is not possible or results are not available, staging can be 
done based solely on imaging and physical exam. In this case, the 
stage is annotated with the prefix "c" to indicate clinical staging 
without biopsy information. 
 
  
T: Tumor  
There are several different categories of primary tumor classification 
based mainly on the size or extent of local invasion of the tumor. 
Typically the T is determined by imaging studies, although in the 
case of some palpable masses this can be supplemented by direct 
measurement. 
 
  
For certain cancers, including breast, carcinoma in situ is staged Tis, 
and grouped as Stage 0. 
 
  
Table 1. 
T Stage Breast Cancer Lung Cancer 
T1 Tumor < 2cm  
(largest dimension) 
Tumor < 3cm  
(largest dimension) 
T2 Tumor > 2cm and < 5cm Tumor > 3cm and < 7cm 
T3 Tumor > 5 cm Tumor > 7 cm 
T4 Tumor invaded chest wall, 
skin, or other neighboring 
structures 
Tumor invaded 
mediastinum, heart, or other 
neighboring structures 
 
 
Note: If there is no detectable primary tumor, but there is nodal or 
metastatic disease, the classification T0 is used. Tis is used to designate in 
situ disease with no risk of nodal involvement or metastasis. If the tumor 
has grown sufficiently large that it directly invades neighboring organs, it 
typically is classified T4 even if the tumor itself is relatively small. 
 
  
N: Node  
The definition of a regional lymph node varies by the tumor location 
and local anatomy. N0 is used to indicate the lack of any suspicious 
lymph nodes on imaging and exam, or pathology. 
 
  
If the patient has enlarged lymph nodes on exam or imaging, ideally 
these should be biopsied to determine if there is any malignancy 
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present. If biopsy cannot be performed, is non-diagnostic, or is 
negative in the face of substantial clinical suspicion, the clinician may 
opt for the classification Nx. This indicates that node status cannot 
be assessed clinically. Often this Nx status is revised following 
surgical resection, although this may not be possible if the patient 
receives chemotherapy or radiation therapy prior to node dissection 
(neoadjuvant therapy). 
  
If regional lymph nodes are found to have malignant cells, the 
number and location of the involved nodes is designated with N1, 
N2, and N3 classifications. Table 2 illustrates the AJCC N 
classifications for breast and lung cancer. 
 
  
Table 2. AJCC N classifications for breast and lung cancer 
N Stage Breast Cancer Lung Cancer 
N0 No regional lymph node 
involvement 
No regional lymph node 
involvement 
N1 Ipsilateral axillary nodes 
(freely mobile) 
Ipsilateral intrapulmonary, 
peribronchial, or hilar nodes 
N2 Ipsilateral axillary nodes 
(fixed or matted) OR  
ipsilateral internal mammary 
nodes  
Ipsilateral mediastinal or 
subcarinal nodes 
N3 Ipsilateral infraclavicular 
nodes or ipsilateral 
supraclavicular nodes OR 
both axillary and internal 
mammary nodes 
Contralateral nodes or 
supraclavicular nodes 
 
 
Note: If nodes have previously been removed for another purpose, the 
patient is defined as Nx. There are many subclassifications regarding the 
type of cells seen and the number of nodes involved, designated N1a, N1b, 
etc. 
 
  
M: Metastasis  
Metastases are distant spread of disease to unrelated organs via 
either hematogenous or lymphatic spread. Metastatic disease is 
assessed both via a complete physical exam and imaging studies.  
Neurological signs and new, localized bone pain are frequent 
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warning signs for metastasis. Bone scans, PET, and head CT are 
often used to check for metastasis in patients with a high clinical 
suspicion. This may be based on symptoms or exam findings, or may 
be due to a high T or N status. Typically M classification correlates 
with higher T and N stages, although it is possible to have metastasis 
with T1 or N0 disease. 
  
If there is evidence of distant metastasis, the patient is classified M1.  
Otherwise the patient is M0. Occasionally the Mx classification is 
used if there is high suspicion but no clinical or radiographic 
evidence of distant disease. 
 
  
TNM to Staging  
Once the TNM classification is determined, this can be used to 
determine the clinical or pathologic stage of disease. There are 
typically at least 32 different TNM classifications possible (T1-4, N0-
3, M0-1), even without considering various modifiers and subclasses.  
This is an unwieldy number that is not necessary for high-level 
discussion of disease severity and potential treatment response. 
Therefore the many different TNM categories are grouped into 
Stages I-IV. Typically metastatic disease (M1) is Stage IV, regardless 
of the T or N classification. Based on the AJCC Staging Manual, ,7th 
edition, a simplified example is shown in Table 3: 
 
  
Table 3. AJCC lung cancer staging 
Lung Cancer N0 N1 N2 N3 
T1 T1N0M0 T1N1M0 T1N2M0 T1N3M0 
T2 T2N0M0 T2N1M0 T2N2M0 T2N3M0 
T3 T3N0M0 T3N1M0 T3N2M0 T3N3M0 
T4 T4N0M0 T4N1M0 T4N2M0 T4N3M0 
Any T AnyTAnyNM1 
 
 
Lung Cancer: 
Green:     Stage I (T1N0M0) 
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Blue:       Stage II (T1N1M0, T2N0M0, T2N1M0, T3N0M0) 
Orange:   Stage III (T1N2M0, T2N2M0, T3N1M0, T3N2M0, T4N0M0, 
                             T4N1M0, T4N2M0, anyTN3M0) 
                Stage IIIA (T1N2M0, T2N2M0, T3N2M0) 
               Stage IIIB (anyTN3M0, T4anyNM0) 
Red:       Stage IV (anyTanyNM1) 
  
Pathology  
If the tumor and/or regional nodes are removed surgically, more 
extensive pathological examination is performed. This does not 
change the patient's clinical staging, which reflects the state of the 
malignancy prior to the initiation of treatment. The post-surgical 
information can be annotated with the prefix "p" to designate a 
pathological stage (pTNM). The American College of Surgeons 
requires pretreatment staging on the chart of each patient, which is 
clinical. All patients can be staged clinically. Pathologic staging 
provides far more accurate information and is the one most 
physicians use if available. 
 
  
If patients receive neoadjuvant chemotherapy or radiotherapy, the 
size of the tumor (T), number of involved nodes (N), and presence of 
metastasis (M) might all be reduced. This does not change the 
patient's official staging, although the new information may be 
annotated with the prefix "yp" to designate a pathological stage after 
neoadjuvant treatment. The ypTNM stage does not take the place of 
the TNM stage, but can provide additional information. 
 
  
Leukemia, Brain Cancer, etc  
Some malignancies are not easily described by the TNM system.  
Due to their diffuse nature, leukemias are not staged. Accurate 
pathologic description of leukemias (e.g., acute vs. chronic, myeloid 
vs. lymphoid, etc.) is very important in determining prognosis and 
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treatment options for patients. In contrast to leukemias, primary 
cancers of the brain rarely spread outside of the brain. T stage is 
relevant in brain tumors. It should be readily apparent that the N and 
M components of the TNM system are meaningless for a malignancy 
that does not spread away from its primary organ. Like leukemias, 
the pathologic description of brain tumors is critically important to 
predicting prognosis and guiding treatment options for patients. 
  
Progression  
A patient’s tumor will retain the initial clinical or pathologic staging 
regardless of disease development. If the primary tumor progresses 
(T), develops nodal involvement (N) or metastasizes (M), the 
patient’s disease stage does not change, but is noted that the 
disease has progressed along certain dimensions. The term 
restaging is heard very often when a reassessment of the current 
state of a patient’s disease is needed, but is a misnomer because it 
confuses people. 
 
  
Revisions of Staging Systems  
Since the goal of the staging system is to provide prognostic 
information to the patient and to compare groups of patients with 
similar prognosis, the staging system for a given cancer may be 
revised over time based on a review of outcomes for a large number 
of patients. In addition, changes in technology, usually imaging 
technology, may lead to improvements in staging systems. 
 
  
As imaging improves (for example as CT or PET scans become 
more available), suspicious nodes may be visualized, moving 
patients into a higher stage grouping than they would have been in 
based only on older imaging and physical examination. This group of 
patients will do better than expected for the new higher stage, but 
would have had the worst prognosis in the former, lower stage. 
Will Rogers, a famous 
American comedian from 
Oklahoma, stated that when 
the Okies moved to California 
(during the Dust Bowl era) 
they improved the intelligence 
of both Oklahoma and 
California. 
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Therefore, moving them improves the outcome of both the lower and 
the higher stage overall. This effect is referred to as the Will Rogers 
effect. These changes and the reasons behind them, are very 
important to understand which staging version was used when a data 
driven oncology paper is considered, both academically and 
clinically. 
  
Thought Questions  
1. What did Will Rogers mean when he said that "When the 
Okies moved to California (during the Dust Bowl era) they 
improved the intelligence of both Oklahoma and California." 
Why is it important to understand "the Will Rogers Effect" in 
oncology? 
 
2. Why do oncologists not change the stage of a patient when 
they "restage" that patient? What are they trying to 
accomplish by "restaging"? 
 
3. What is the difference between clinical staging and pathologic 
staging? If staging is based on diagnostic imaging, what is 
that called? 
 
4. How do advances in imaging affect staging?  
5. Prior to 2011, non-small cell lung cancers presenting with 
malignant pleural effusions were considered stage IIIb 
disease. Beginning in January, 2011, these lung cancers 
were reclassified as stage IV. How do staging system 
revisions affect interpretation of clinical studies? How could 
the 2011 change in the lung cancer staging be considered an 
example of "the Will Rogers effect"? 
 
  
Glossary  
Cancer stage- Describes disease extent, provides prognostic 
information and guides treatment decisions 
 
Clinical staging- Initial radiography and exam findings  
CT- X-ray computed tomography, a series of X-rays that are digitally 
processed to produce a 3 dimensional map of the density of the body 
part being imaged. The patient receives a higher dose of radiation 
than is received in an X-ray. 
 
Grade- A determination of how well or poorly differentiated cancer 
cells appear to be based on microscopic assessment of a tumor 
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specimen 
MRI- Magnetic resonance imaging, a medical imaging technique 
wherein the patient is placed in a strong magnetic field. In such 
fields, hydrogen nuclei give different responses to low-energy radio 
frequencies according to the local chemical environment. From these 
responses, 3 dimensional maps of body tissue types are produced. 
MRI scans are not associated with radiation exposure and are useful 
in contrasting soft tissues. 
 
Neoadjuvant- Administration of a therapy in preparation for a main 
treatment. Examples include hormone therapy, radiation therapy and 
chemotherapy, which may shrink the tumor and make the main 
treatment safer and/or more effective. 
 
Pathologic staging- Obtained from surgical specimens  
PET Scan- Positron emission tomography, a medical imaging 
technique wherein positron-emitting tracer is incorporated into 
(usually) a glucose analog and injected into the body. The complex is 
taken up by the body tissues, with greater uptake in metabolically 
active areas. As positrons are emitted, they collide with electrons, 
and produce pairs of gamma ray photons moving in opposite 
directions, which are detected and localized. This forms a 3-
dimensional map of areas of maximal tracer uptake in the body. 
 
TNM Staging System- A common staging system developed by the 
American Joint Committee on Cancer 
 
X ray- Photons with a shorter wavelength than ultraviolet light are 
created and passed through the tissues of interest. Dense objects 
absorb more of the photons, casting a shadow on the sensor on the 
other side of the body part. 
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